ED Visits Signal Cancer Risk and New Treatments Reshape Oncology Care

Emergency departments may be an underutilized gateway for catching cancer earlier. A large national insurance claims study found that one in four patients newly diagnosed with cancer had visited an ER shortly before diagnosis, with those visits producing only vague, nonspecific findings. This points to a systemic gap: opportunities to flag cancer risk are being missed in acute care settings, potentially delaying life-saving treatment.

On the treatment front, two notable FDA approvals arrived. Pegfilgrastim-pccg (Ennumo), the eighth biosimilar to Neulasta, was approved to prevent neutropenia — dangerous low white blood cell counts — caused by chemotherapy. Sanofi also received approval for subcutaneous isatuximab (Sarclisa Escena) for multiple myeloma, notable as the first anticancer agent delivered via an on-body injector, potentially improving patient convenience and adherence.

A nationwide study exposed a severe radiation oncology access crisis: more than 50 million Americans, spanning nearly 70% of U.S. counties, have no local radiation oncology providers. This geographic disparity threatens equitable cancer care. In response, eight community-based clinics across five states formed the Anoma Cancer Collective to maintain independent, nonprofit radiation services.

In research highlights, an investigational immunotherapy nearly doubled progression-free survival in newly diagnosed glioblastoma patients — a notoriously difficult-to-treat brain cancer. Separately, researchers at Roswell Park identified new mechanisms by which obesity promotes lung cancer development and growth, reinforcing the metabolic-oncology connection relevant to longevity-focused individuals.

AI is also proving its value: automated lung nodule detection on standard X-rays saved five low- and middle-income countries over $400 million across five years. Caveats include that most findings here are summaries of separate studies with varying methodologies, and primary sources should be consulted before drawing clinical conclusions.